Broadfin Capital’s Gyre Therapeutics GYRE Stock Holding History

Broadfin Capital’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-380	Closed	-$1.24M	–	87
2013 Q4	$1.24M	Buy	+380	New	+$1.5M	0.16%	57

Other funds holding GYRE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Broadfin Capital's GYRE Position: Q1 2014 in Review

Broadfin Capital sold out of Gyre Therapeutics (GYRE) in Q1 2014, closing a stake of 380 shares — an estimated $1.24M sold.

Broadfin Capital first reported a position in GYRE in Q4 2013 and held it in 1 quarter. The position peaked at $1.24M in Q4 2013. 64 funds tracked by Wall St. Rank hold GYRE as of Q1 2014.

Broadfin Capital reported no remaining Gyre Therapeutics position as of Q1 2014 after selling out during the quarter.
Broadfin Capital sold 380 Gyre Therapeutics shares in Q1 2014, an estimated $1.24M.
Broadfin Capital first reported a position in Gyre Therapeutics in Q4 2013 and held it in 1 quarter.
Broadfin Capital's Gyre Therapeutics position peaked at $1.24M in Q4 2013.
64 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2014.

Based on Broadfin Capital's 13F filing for Q1 2014, filed 15 May 2014.